Sarah Lavelle

Wow.

And HIMS's response was, Since launching the compounded synaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry.

As a result, we have decided to stop offering access to this treatment.

This suggests GLP-1-based therapies may influence not only food cravings but also substance use, highlighting a broader role for these drugs in regulating reward-driven behavior.